Literature DB >> 17241584

Mixed vitiligo.

Sanjeev V Mulekar1, Ahmed Al Issa, Marwan Asaad, Bassel Ghwish, Abdullah Al Eisa.   

Abstract

BACKGROUND: There are two commonly recognized forms of vitiligo-generalized and localized. This classification is important to understand the course of the disease and its prognosis. Most patients have generalized vitiligo; few patients have both segmented and generalized vitiligo. OBSERVATION: We report four more cases of mixed vtiligo, segmental with generalized type. This report is only the second to present a case of segmental with generalized vitiligo.
CONCLUSION: Mixed vitiligo is not yet part of a standard classification. Its etiology is not yet fully defined. Further research is required to understand the course and prognosis of mixed vitiligo.

Entities:  

Mesh:

Year:  2006        PMID: 17241584     DOI: 10.2310/7750.2006.00018

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  4 in total

1.  Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference.

Authors:  K Ezzedine; H W Lim; T Suzuki; I Katayama; I Hamzavi; C C E Lan; B K Goh; T Anbar; C Silva de Castro; A Y Lee; D Parsad; N van Geel; I C Le Poole; N Oiso; L Benzekri; R Spritz; Y Gauthier; S K Hann; M Picardo; A Taieb
Journal:  Pigment Cell Melanoma Res       Date:  2012-05       Impact factor: 4.693

2.  Profile of vitiligo in kumaun region of uttarakhand, India.

Authors:  Saurabh Agarwal; Amit Ojha; Shalini Gupta
Journal:  Indian J Dermatol       Date:  2014-03       Impact factor: 1.494

3.  Role of histamine as a toxic mediator in the pathogenesis of vitiligo.

Authors:  Salil Kumar Panja; Biman Bhattacharya; Sitesh Chandra Lahiri
Journal:  Indian J Dermatol       Date:  2013-11       Impact factor: 1.494

4.  Segmental and generalized vitiligo: both forms demonstrate inflammatory histopathological features and clinical mosaicism.

Authors:  Venkat Ratnam Attili; Sasi Kiran Attili
Journal:  Indian J Dermatol       Date:  2013-11       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.